Chronic hepatitis C: Burden of disease and cost associated with hospitalisations in France in 2012 (The HEPC-LONE study)

Abergel, Armand; Rotily, Michel; Branchoux, S.; Akremi, Raoudha; Léotoing, Lucie de; Vainchtock, Alexandre; Gaudin, Anne-Françoise

doi:10.1016/j.clinre.2015.08.006

Cited by 12 publications

(10 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Health spending in France has been estimated at 191 billion €, of which the costs of managing the hepatic complications of HCV infection contributes a sizable part . In a retrospective hospital database analysis, 22 056 hospital stays were considered to be directly related to liver complications of HCV infection with a total cost estimated to be 61 million €. By contrast, we have estimated that the cost of extrahepatic manifestations related to HCV infection was 215 million €.…”

Section: Discussionsupporting

confidence: 82%

Direct medical costs associated with the extrahepatic manifestations of hepatitis C virus infection in France

Cacoub

Vautier

Desbois

et al. 2017

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 82%

Direct medical costs associated with the extrahepatic manifestations of hepatitis C virus infection in France

Cacoub

Vautier

Desbois

et al. 2017

Aliment Pharmacol Ther

View full text Add to dashboard Cite

“…However, according to WHO data, and before the introduction of the hepatitis B vaccine into the vaccination program, Morocco was considered to have an intermediate prevalence of hepatitis B [1, 2]. By comparing the values of our study with those of other countries, we find that our figures are higher than those observed in France (0.065%) [15]. However, the prevalence of HBs Ag in our series is lower than that observed in Tunisia (3.6%) [16] and Mauritania (20.3%) [17].…”

Section: Discussionmentioning

confidence: 60%

Prevalence of hepatitis B and C in blood transfusion center, Oujda Morocco (2013-2015)

Boubker¹,

Zerrouki²,

Sidqi³

et al. 2019

Pan Afr Med J

View full text Add to dashboard Cite

Viral hepatitis is a serious public health problem. Its epidemiology is not precisely known in Morocco. Our objective was to assess the prevalence of HBV and HCV in a particular population of “blood donors” at the Regional Blood Transfusion Centre in Oujda. A retrospective study was conducted from May 1, 2013 to May 31, 2015. Thirty-one thousand nine hundred and fifty-two blood donors were tested. Antigen detection was made according to ELISA technique (MonolisaTMHBs Ag ULTRA). HCV research was performed by ELISA using the kit « Monolisa HCV Ag-Ab ULTRA ». 177 blood donors included, they are divided into 155 male (87.6%) and 22 female (12.4%) subjects with a ratio of 7. The average age was 37.64 ± 12 years. Six cases were positive for HCV with an overall prevalence of 0.02%. The population study by sex shows a prevalence of 0.004% for 23177 male sera and 0.057% for 8775 female sera. Six donors were HCV positive, of which 05 were female (83.33%) and one was male (16.66%). The average age was 43 ± 14 years. Co-infection with HCV HBV-HCV and HCV-Syphilis and HCV-HIV are absent. Co-infection with HBV and HIV was found in one case. HBV-syphilis co-infection was found in 04 cases. Chronic viral hepatitis is a real global health problem. Its prevalence is currently estimated at 0.55% for HBV and 0.02% for HCV, reclassifying Morocco as a low endemic area. The prevention remains the most effective method to successfully control HBV and HCV infection.

show abstract

“… 20 Subjects with HCC (C220 and C229) who were prescribed DAA therapy (638101ATB [daclatasvir], 638001ACH [asunaprevir], 644401ATB [sofosbuvir], 645800ATB [ledipasvir/sofosbuvir], 223604ACH, 223601ACH, and 223601ACH [ribavirin]) between August 2015 and December 2016 were extracted from the HIRA database using the International Classification of Diseases (10th edition). 21 , 22 The exclusion criteria were as follows: autoimmune hepatitis (K75.4) or viral co-infection, including those with the hepatitis B (B18.0, B18.10, B18.18, B18.1, and Z22.5) and the human immunodeficiency virus (Z21.X, Z86.X, B20.X, B21.X, B22.X, B23.X, and B24.X); liver transplantation before DAA therapy; history of DAA therapy before or during HCC treatment. HCC recurrence was defined as reinitiation of HCC treatment after DAA therapy.…”

Section: Methodsmentioning

confidence: 99%

Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C

et al. 2021

View full text Add to dashboard Cite

Background/Aims This study was performed to evaluate the efficacy of direct-acting antivirals (DAAs) in Korean patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) and to investigate the risk factors associated with HCC recurrence. Methods A total of 100 patients with HCV-related HCC, who were treated with DAAs between May 2015 and December 2016, were recruited from seven university hospitals in Korea. Claim data of 526 patients with HCC obtained from the Health Insurance Review and Assessment Service in South Korea were used for external validation of the results. Results Among the 100 patients, 88% achieved a sustained virological response (SVR) 12 weeks after the end of DAA therapy (SVR12), and 37% experienced HCC recurrence after DAA therapy. Short last HCC treatment durability (<12 months) before DAA commencement was independently associated with HCC recurrence (hazard ratio [HR], 2.89; p=0.011). In the nationwide validation cohort, 20.3% of the patients experienced HCC recurrence. The last HCC treatment with a noncurative method, a short last HCC treatment durability (<12 months), and a longer total duration of HCC treatment (≥18 months) were independently related with HCC recurrence (HR 3.73, p<0.001; HR 3.34, p<0.001; and HR 1.74, p=0.006; respectively). Conclusions DAA therapy showed an acceptable SVR12 rate in patients with HCV-related HCC. Short last HCC treatment durability (<12 months) was associated with HCC recurrence after DAA therapy. This finding suggests that the last HCC treatment durability is an important predictor of HCC recurrence after DAA therapy. (Gut Liver 2021;15-419)

show abstract

Chronic hepatitis C: Burden of disease and cost associated with hospitalisations in France in 2012 (The HEPC-LONE study)

Cited by 12 publications

References 11 publications

Direct medical costs associated with the extrahepatic manifestations of hepatitis C virus infection in France

Direct medical costs associated with the extrahepatic manifestations of hepatitis C virus infection in France

Prevalence of hepatitis B and C in blood transfusion center, Oujda Morocco (2013-2015)

Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C

Contact Info

Product

Resources

About